11.87
-0.04 (-0.34%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Alumis Inc. | - | - |
Stockmoo Score
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 30 Jun 2024 | 10,645,965 |
| Foresite Capital Management V, Llc | 30 Jun 2024 | 5,584,887 |
| Venbio Partners Llc | 30 Jun 2024 | 2,826,048 |
| Sr One Capital Management, Lp | 30 Jun 2024 | 1,959,896 |
| Yu Fan | 30 Jun 2024 | 789,618 |
| Omega Fund Management, Llc | 30 Jun 2024 | 653,225 |
| Ally Bridge Group (Ny) Llc | 30 Jun 2024 | 618,750 |
| Iron Triangle Partners Lp | 30 Jun 2024 | 125,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 36.00 (Morgan Stanley, 203.29%) | Buy |
| Median | 30.50 (156.95%) | |
| Low | 13.00 (Cantor Fitzgerald, 9.52%) | Buy |
| Average | 27.50 (131.68%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 12.60 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 23 Jul 2024 | 13.00 (9.52%) | Buy | 12.60 |
| Guggenheim | 23 Jul 2024 | 32.00 (169.59%) | Buy | 12.60 |
| Leerink Partners | 23 Jul 2024 | 29.00 (144.31%) | Buy | 12.60 |
| Morgan Stanley | 23 Jul 2024 | 36.00 (203.29%) | Buy | 12.60 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Sep 2024 | Announcement | Alumis to Participate in Upcoming September Investor Conferences |
| 13 Aug 2024 | Announcement | Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements |
| 29 Jul 2024 | Announcement | Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |